The association between KRAS mutations and response to EGFR inhibitors has been established in multiple studies; consequently, KRAS genotyping is recommended in all patients with metastatic colorectal cancer (mCRC) before any therapy that utilizes the EGFR-targeted monoclonal antibodies, cetuximab or panitumumab [1]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.